Evaluation of the Regulatory Required Post-Authorization Safety Study for Propacetamol: Nested Case-Control and Case-Time-Control Studies
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Following the withdrawal of propacetamol in Europe owing to safety issues, the regulatory authority of South Korea re quested a post-marketing surveillance study to investigate its safety profile. Materials and Methods: We conducted nested case-control and case-time-control (CTC) analyses of cases and controls identified for outcomes of interest, including anaphylaxis, thrombosis, and Stevens–Johnson syndrome (SJS), using the claims database of South Korea, 2010–2019. Risk-set sampling was used to match each case with up to 10 controls for age, sex, cohort entry date, and follow-up duration. Exposure to anaphylaxis, thrombosis, and SJS was assessed within 7, 90, and 30 days of the index date, respec tively. We calculated odds ratios (OR) with 95% confidence intervals (CIs) using conditional logistic regression to assess the risk of outcomes associated with propacetamol. Results: We identified cases of anaphylaxis (n=61), thrombosis (n=95), and SJS (n=1) and matched them to controls (173, 268, and 4, respectively). In the nested case-control analysis, the ORs for anaphylaxis and SJS were inestimable given the small num ber of propacetamol users during the risk period; meanwhile, the OR for thrombosis was 1.60 (95% CI 0.71–3.62). In the CTC de sign, the effect estimate was only estimated for thrombosis (OR 0.56, 95% CI 0.09–3.47). Conclusion: In both nested case-control and CTC analyses, propacetamol was not associated with an increased risk of anaphy laxis, thrombosis, or SJS. The findings from this study, which used routinely collected clinical data, provide reassuring real-world evidence regarding the safety of propacetamol in a nationwide population to support regulatory decision-making.
Abstract
Purpose: Following the withdrawal of propacetamol in Europe owing to safety issues, the regulatory authority of South Korea re quested a post-marketing surveillance study to investigate its safety profile. Materials and Methods: We conducted nested case-control and case-time-control (CTC) analyses of cases and controls identified for outcomes of interest, including anaphylaxis, thrombosis, and Stevens–Johnson syndrome (SJS), using the claims database of South Korea, 2010–2019. Risk-set sampling was used to match each case with up to 10 controls for age, sex, cohort entry date, and follow-up duration. Exposure to anaphylaxis, thrombosis, and SJS was assessed within 7, 90, and 30 days of the index date, respec tively. We calculated odds ratios (OR) with 95% confidence intervals (CIs) using conditional logistic regression to assess the risk of outcomes associated with propacetamol. Results: We identified cases of anaphylaxis (n=61), thrombosis (n=95), and SJS (n=1) and matched them to controls (173, 268, and 4, respectively). In the nested case-control analysis, the ORs for anaphylaxis and SJS were inestimable given the small num ber of propacetamol users during the risk period; meanwhile, the OR for thrombosis was 1.60 (95% CI 0.71–3.62). In the CTC de sign, the effect estimate was only estimated for thrombosis (OR 0.56, 95% CI 0.09–3.47). Conclusion: In both nested case-control and CTC analyses, propacetamol was not associated with an increased risk of anaphy laxis, thrombosis, or SJS. The findings from this study, which used routinely collected clinical data, provide reassuring real-world evidence regarding the safety of propacetamol in a nationwide population to support regulatory decision-making.
참고문헌 (25)
- McNicol ED, "Single dose intravenous paracetamol or intravenous propacetamol for postoperative pain", Cochrane Database Syst Rev, 2016, pp.CD007126~ (2016)
- "Meeting highlights from the Committee for Medicinal Products for Human Use, 21–24 September 2009"[URL]
- Lee HY, "Propacetamol poses a potential harm of adverse hypotension in male and older patients", Pharmacoepidemiol Drug Saf, 26, pp.256~264 (2017)
- Seo Y, "Clinical features of serious adverse drug reactions in a tertiary care hospital in Korea", Korean J Med, 92, pp.392~400 (2017)
- Kwon JS, "Analysis of adverse drug reactions related analgesics collected by spontaneous reporting program within a hospital", JPERM, 9, pp.18~26 (2017)
- Barbaud A, "Occupational allergy to propacetamol", Lancet, 346, pp.902~ (1995)
- De Coninck AL, "Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances", Dermatology, 193, pp.338~341 (1996)
- Gielen K, "Occupational allergic contact dermatitis from drugs in healthcare workers", Contact Dermatitis, 45, pp.273~279 (2001)
- Jeong HE, "A study of the regional differences in propacetamol-related adverse events using VigiBase data of the World Health Organization", Sci Rep, 12, pp.21568~ (2022)
- Yoo S, "Data resource profile : the allergic disease database of the Korean national health insurance service", Epidemiol Health, 43, pp.e2021010~ (2021)
- Yang MS, "Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis : a nationwide population-based study using national health insurance database in Korea", PLoS One, 11, pp.e0165933~ (2016)
- Suissa S, "Pharmacoepidemiology", pp.811~829 (2005), John Wiley & Sons
- Montañez MI, "Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis", Front Immunol, 8, pp.614~ (2017)
- Vinogradova Y, "Use of hormone replacement therapy and risk of venous thromboembolism : nested case-control studies using the QResearch and CPRD databases", BMJ, 364, pp.k4810~ (2019)
- Abe J, "Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report database", J Pharm Health Care Sci, 2, pp.14~ (2016)
- Kim EJ, "Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen", Asia Pac Allergy, 4, pp.68~72 (2014)
- Schwartz RA, "Toxic epidermal necrolysis : part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis", J Am Acad Dermatol, 69, pp.173~ (2013)
- Austin PC, "Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples", Stat Med, 28, pp.3083~3107 (2009)
- Suissa S, "The case-time-control design", Epidemiology, 6, pp.248~253 (1995)
- Consiglio GP, "Case-crossover study design in pharmacoepidemiology : systematic review and recommendations", Pharmacoepidemiol Drug Saf, 22, pp.1146~1153 (2013)
- Barbaud A, "Occupational contact dermatitis to propacetamol. Allergological and chemical investigations in two new cases", Dermatology, 195, pp.329~331 (1997)
- Choi SJ, "The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children : a multicenter, randomized, doubleblind, comparative, phase 3 clinical trial", BMC Pediatr, 18, pp.201~ (2018)
- Irish C, "Skin and soft tissue infections and vascular disease among drug users, England", Emerg Infect Dis, 13, pp.1510~1511 (2007)
- Wu J, "Use of real-world evidence in regulatory decisions for rare diseases in the United States-current status and future directions", Pharmacoepidemiol Drug Saf, 29, pp.1213~1218 (2020)
- Cave A, "Real-world data for regulatory decision making : challenges and possible solutions for Europe", Clin Pharmacol Ther, 106, pp.36~39 (2019)